Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06448910
Other study ID # Lung-AK104
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date June 2024
Est. completion date June 2027

Study information

Verified date June 2024
Source Fudan University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this single arm, phase II clinical trial is to evaluate the efficacy and safety of cadonilimab (AK104) as induction and consolidation therapy in locally advanced/unresectable non-small cell lung cancer (NSCLC) patients treated with concurrent chemoradiotherapy. Participants will receive 2 cycles of induction therapy with cadonilimab combined with EP regimen, followed by standard concurrent chemoradiotherapy (thoracic radiotherapy +EP regimen chemotherapy), and finally consolidation therapy with cadonilimab (AK104) for 1 year.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 41
Est. completion date June 2027
Est. primary completion date June 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - 1. Age: 18-75 years old; 2. ECOG physical status: 0-1; 3. The expected survival time is more than 3 months; 4. Patients with locally advanced/unresectable stage IIIA-C NSCLC confirmed by histopathology or cytology based on the AJCC 8th edition staging system at initial diagnosis 5. Did not receive any anti-tumor treatment; 6. No known sensitive EGFR/ALK/ROS1 mutations 7. According to RECIST criteria, at least one measurable lesion must be used as the target lesion 8. Good organ function = 7 days before the first dose of study drug, as indicated by the following laboratory values: 1. Absolute neutrophil count (ANC) =1.5 x 109/L, platelet =100 x 109/L, hemoglobin =90g/L; 2. INR or PT =1.5 x ULN; 3. aPTT =1.5 x ULN; 4. Total serum bilirubin =1.5 x ULN; 5. AST and ALT = 2.5x ULN or =5×ULN in patients with liver metastases; 6. albumin =25 g/L (2.5 g/dL); 7. Serum creatinine =1.5 times the upper limit of normal value (ULN), or serum creatinine clearance calculated by Cockcroft-Gault formula >50 mL/min; 9. Informed consent signed by patients or their legal representatives was obtained, and the study protocol and follow-up procedure were followed. 10. Patients of childbearing potential had to be willing to continue using high-potency contraception for the duration of the study and for =120 days after the last dose of Cadonilimab (AK104). Exclusion Criteria: 1. Pathological types of mixed small cell and non-small cell lung cancer; Patients with known EGFR/ALK/ROS1 mutations; 2. 3. Patients have received an approved systemic anticancer therapy or systemic immunomodulatory agent (including, but not limited to, interferon, interleukin-2, and tumor necrosis factor) within 4 weeks before the first dose; 4. Have received a live or attenuated live vaccine within 4 weeks before enrollment or are expected to require a live or attenuated live vaccine during the study or within 5 months after the last dose of Cadonilimab (AK104); 5. Patients allergic to Cadonilimab(AK104) or any of the ingredients, or the container; 6. Untreated patients with chronic hepatitis B or chronic hepatitis B virus carriers with HBV DNA=500 IU/mL or patients with active hepatitis C: Patients with inactive HBsAg carriers and medically stable active HBV infection (HBV DNA<500 IU/mL) were eligible. Only to hepatitis b core antibody (anti HBc antibody) patients who tested positive for HBV DNA testing. Patients who were negative for hepatitis C virus (HCV) antibodies at screening or who were positive for HCV antibodies at screening and subsequently tested negative for HCV RNA were eligible. HCV RNA testing will be performed only in patients who are positive for hepatitis C virus (HCV) antibodies. Note: the hepatitis b surface antigen (HBsAg) can be detected or patients with HBV DNA can be detected, should according to the guidelines for treatment. Patients receiving antiviral treatment at screening were supposed to have been on treatment for more than 2 weeks before enrollment and to have continued treatment for 6 months after discontinuation of the study drug. 7. Need systemic treatment of active autoimmune disease, the researchers reckon have an impact on research and treatment of patients; 8. Any condition requiring systemic treatment with a corticosteroid (prednisone or equivalent >10 mg/ day) or other immunosuppressive agent, within 14 days before the first dose of the study drug, that was assessed by the investigator as having an impact on the study treatment; 9. Severe chronic or active infection (including tuberculosis infection, etc.) requiring antimicrobial, antifungal, or antiviral systemic therapy within 14 days prior to the first dose of study drug 10. Always allogeneic stem cell transplantation or organ transplantation; 11. Meet the following any kind of cardiovascular risk factors of standard: 1. Cardiogenic chest pain =28 days before the first dose of study drug, defined as moderate pain that limits instrumental exercise of daily living; 2. Symptomatic pulmonary embolism =28 days before the first dose of study drug; 3. Any history of acute myocardial infarction =6 months before the first dose of study drug; 4. Any history of New York Heart Association (NYHA) class III or IV heart failure =6 months before the first dose of study drug; 5. Any ventricular arrhythmic event of grade =2 occurred =6 months before the first dose of study drug. 6. History of any cerebrovascular accident =6 months before the first dose of study drug; 7. Corrected QT interval (QTc) (corrected with Fridericia's method) >450 msec; Note: If the QTc interval on the initial ECG was >450 ms, a subsequent ECG was performed to rule out the result 8. Left ventricular ejection fraction (LVEF) = the lower limit of normal (LLN) as assessed by echocardiography (ECHO); 9. Any syncope or seizure occurring =28 days before the first dose of study drug; 12. Patients with uncontrolled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg); 13. Bleeding, thrombotic disorders, or use of an anticoagulant (e.g., warfarin) or similar medication requiring therapeutic INR monitoring within 6 months before the first dose of a study drug that, in the investigator's judgment, may have influenced treatment; 14. Patients with any sign or history of bleeding that was assessed by the investigator as having an impact on the study protocol; Patients who had any bleeding event of grade 3 or higher, nonhealed wound, ulcer, or fracture within 4 weeks before the first dose; 15. Hemoptysis > 50ml/d; 16. The central cavity or tumor was shown to invade or be adjacent to large vessels by imaging studies, and the tumor was assessed by the investigator as likely to invade large vessels and cause fatal bleeding. 17. Unable to swallow capsules or significant influence disease or a history of gastrointestinal function, such as malabsorption syndrome, stomach or intestinal resection, bariatric surgery, with symptoms of inflammatory bowel disease, or incomplete or complete intestinal obstruction. 18. Patients requiring treatment with gastric ph-regulating drugs, including proton pump inhibitors and/or H2 antagonist drugs. Patients can convert antacids; 19. Patients with a history of uncontrolled systemic diseases, including diabetes mellitus, hypertension, pulmonary fibrosis, or acute lung disease, that were assessed by the investigator as having an impact on the study treatment; 20. Patients with a history of major illness or clinical manifestations that may affect the function of organ systems and are considered by the investigator to have an impact on the study treatment; 21. Had undergone any major surgery requiring general anesthesia within 28 days or less before the first dose; 22. There are underlying medical conditions or alcohol/drug abuse or dependence that contraindicate the use of the experimental drug or preclude the administration of the study drug, or may affect the interpretation of the results, or place the patient at a high risk of treatment complications; 23. Known human immunodeficiency virus (HIV) infection; 24. Any activity before the group 2 years or less malignant tumor, except in the study of the specific cancer and any local recurrence has been cured of cancer (such as removal of basal cell or squamous cell cancer, superficial bladder cancer, cervical or breast carcinoma in situ); 25. Pregnant or lactating women, or male and female patients who plan to have a child during the study period; 26. Participate in another therapeutic clinical study at the same time, unless it is an observational (nonintervention) clinical study or is in the follow-up period of an intervention study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cadonilimab (AK104)
Participants will receive 2 cycles of induction therapy with cadonilimab combined with EP regimen, followed by standard concurrent chemoradiotherapy (thoracic radiotherapy +EP regimen chemotherapy), and finally consolidation therapy with cadonilimab (AK104) for 1 year.

Locations

Country Name City State
China Fudan University Shanghai Cancer Center Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate,ORR According to RECISIT1.1 criteria, the proportion of patients achieving CR and PR as their best response before initial disease progression was evaluated. 3 years
Primary The incidence rate of treatment-related adverse events The proportion of treatment-related toxicity to the total number of evaluable cases was evaluated according to CTCAE 5.0 criteria. 3 years
Secondary ORR before Concurrent Chemoradiotherapy Objective response rate was evaluated according to RECIST 1.1 criteria after two courses of Cadonilimab combined with EP chemotherapy and before the start of concurrent chemoradiotherapy 3 years
Secondary disease control rate before Concurrent Chemoradiotherapy Disease control rate was evaluated according to RECIST 1.1 criteria after two courses of AK104 combined with EP chemotherapy and before the start of concurrent chemoradiotherapy 3 years
Secondary Overall survival,OS The time from enrollment to death from any cause. Patients who were still alive at the time of analysis will have the date of their last contact as the cutoff date. 3 years
Secondary Progression free survival,PFS The time from enrollment to disease progression or death from any cause. Patients who were still alive at the time of analysis will have the date of their last contact as the cutoff date. 3 years
Secondary 12 months PFS The proportion of patients who had progression or died from any cause from the first day of enrollment through 12 months among all participants who received at least one dose of Cadonilimab. 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT05821933 - RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC Phase 1/Phase 2
Active, not recruiting NCT03269162 - Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection Phase 3
Recruiting NCT05002270 - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation Phase 1/Phase 2
Recruiting NCT06315686 - The Dynamic Monitoring of Cerebrospinal Fluid ctDNA Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Recruiting NCT05466149 - Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Completed NCT03609918 - Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing
Recruiting NCT06043817 - First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Phase 1/Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT05078931 - A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients Phase 2
Not yet recruiting NCT05547737 - Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
Not yet recruiting NCT05909137 - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Withdrawn NCT05959473 - EGFR_IUO 3.20 Clinical Study Protocol N/A
Not yet recruiting NCT05005468 - A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. Phase 2
Recruiting NCT01690390 - Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease Phase 2
Completed NCT01852578 - Cabazitaxel in Relapsed and Metastatic NSCLC Phase 2
Active, not recruiting NCT01460472 - Immunotherapy With Racotumomab in Advanced Lung Cancer Phase 3
Completed NCT00866970 - Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia Phase 2
Completed NCT00702975 - Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy Phase 2